Nektar Therapeutics/$NKTR
1D1W1MYTD1Y5YMAX
Capital at risk
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
- Ticker
- $NKTR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 63
- Headquarters
- San Francisco, United States
- Website
- www.nektar.com
NKTR Metrics
BasicAdvanced
$1.5B
-
-$6.47
1.16
-
Price and volume
Market cap
$1.5B
Beta
1.16
52-week high
$109.00
52-week low
$33.40
Average daily volume
1.4M
Financial strength
Current ratio
10.416
Quick ratio
9.708
Long term debt to equity
0.125
Total debt to equity
0.151
Interest coverage (TTM)
-4.22%
Profitability
EBITDA (TTM)
-129.95
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-287.84%
Operating margin (TTM)
-239.32%
Effective tax rate (TTM)
-0.04%
Revenue per employee (TTM)
$870,000
Management effectiveness
Return on assets (TTM)
-12.54%
Return on equity (TTM)
-35.75%
Valuation
Price to revenue (TTM)
19.394
Price to book
1.6
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
-4.51
Free cash flow yield (TTM)
-22.17%
Free cash flow per share (TTM)
-9.662
Growth
Revenue change (TTM)
-27.15%
Earnings per share change (TTM)
-25.83%
3-year revenue growth (CAGR)
-14.63%
10-year revenue growth (CAGR)
-11.77%
3-year earnings per share growth (CAGR)
-35.80%
10-year earnings per share growth (CAGR)
-7.77%
What the Analysts think about NKTR
Analyst ratings (Buy, Hold, Sell) for Nektar Therapeutics stock.
Analyst projections of the future price of Nektar Therapeutics stock.
Bulls say / Bears say
In atopic dermatitis, all three rezpegaldesleukin dose groups met the Phase 2b primary endpoint: EASI reductions were 53%–61%, versus 31% on placebo, with key secondary measures also favouring treatment. Publication in The Lancet strengthens the case for the ongoing pivotal programme. (Nektar Therapeutics)
The alopecia areata follow-up suggests hair regrowth may persist after treatment stops: 5 of 8 patients retained a SALT score of 20 or less six months off treatment, while the share with SALT 10 or less rose from 7% at week 52 to 19%. The very small follow-up group limits how confidently this can be generalised. (PR Newswire)
Nektar has started the first Phase 3 atopic dermatitis trials and reports more than $1 billion in cash and investments, with runway into Q3 2028. Management says this should cover the initial Phase 3 readouts expected in mid-2028, reducing near-term funding pressure as the lead drug is tested. (Nektar Therapeutics)
The investment case is heavily reliant on rezpegaldesleukin: Nektar says its business would be significantly harmed if the drug fails to advance. That leaves investors exposed to a major setback in its pivotal trials, despite the company’s earlier-stage pipeline. (StockTitan)
The alopecia areata Phase 2b result carries statistical uncertainty: a specialist review reports that the full modified intention-to-treat analysis missed the primary endpoint, with significance appearing only after four patients with major eligibility violations were excluded. The planned Phase 3 study must show the effect holds without that exclusion. (Merlintrader)
Nektar remains loss-making and has already relied on substantial share issuance: its first-half 2026 loss was $85.5 million, while equity financings raised about $1.07 billion net between July 2025 and April 2026. The stated runway only extends into Q3 2028, so delays or higher trial costs could increase the risk of further dilution. (StockTitan, Nektar Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2026.
NKTR Financial Performance
Revenues and expenses
NKTR Earnings Performance
Company profitability
Upcoming events
No upcoming events
NKTR News
AllArticlesVideos
Funds containing NKTR
AllEURGBPUSD
Fund name | Fund size | $NKTR weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.06% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.02% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.